SEP-363856: Ph II SEP361-201 started

Sumitomo Dainippon’s Sunovion Pharmaceuticals Inc. subsidiary began the double-blind, placebo-controlled, international Phase II SEP361-201 trial to evaluate 50 and 75 mg oral SEP-363856 once daily for 4 weeks in about 240 patients. Patients who complete the trial may enroll in the 26-week, open-label SEP361-202 extension of 25, 50 and 75 mg SEP-363856 once daily in about 180 patients. ...